Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicentre Phase II Randomised Trial of Durvalumab (MEDI4736) Versus Physician's Choice Chemotherapy in Recurrent Ovarian Clear Cell Adenocarcinomas (MOCCA)

NCT03405454 is registered in ClinicalTrials.gov with National University Hospital, Singapore as lead sponsor.

NCT NCT03405454
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03405454 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicentre Phase II Randomised Trial of Durvalumab (MEDI4736) Versus Physician's Choice Chemotherapy in Recurrent Ovarian Clear Cell Adenocarcinomas (MOCCA)
Lead sponsor
National University Hospital, Singapore
Phase
Phase 2
Overall status
Unknown status
Start date
October 9, 2017
Completion date
March 15, 2022
Enrollment
46 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

ovarian clear cell carcinoma